Normal view MARC view ISBD view

Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. [Review]

MedStar author(s):

Citation: Journal of the American College of Cardiology. 74(25):3153-3163, 2019 12 24.PMID: 31856973Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Cardiovascular Diseases/et [Etiology] | *Cytokine Release Syndrome/et [Etiology] | *Immunotherapy, Adoptive/ae [Adverse Effects] | *Neoplasms/th [Therapy] | *Receptors, Chimeric Antigen | Clinical Trials as Topic | Female | Humans | Middle AgedYear: 2019 Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:

0735-1097

Name of journal: Journal of the American College of CardiologyAbstract: Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of patients with relapsed and refractory hematologic malignancies and is increasingly investigated as a therapeutic option of other malignancies. The main adverse effect of CAR T-cell therapy is potentially life-threatening cytokine release syndrome (CRS). Clinical cardiovascular (CV) manifestations of CRS include tachycardia, hypotension, troponin elevation, reduced left ventricular ejection fraction, pulmonary edema, and cardiogenic shock. Although insults related to CRS toxicity might be transient and reversible in most instances in patients with adequate CV reserve, they can be particularly challenging in higher-risk, often elderly patients with pre-existing CV disease. As the use of CAR T-cell therapy expands to include a wider patient population, careful patient selection, pre-treatment cardiac evaluation, and CV risk stratification should be considered within the CAR T-cell treatment protocol. Early diagnosis and management of CV complications in patients with CRS require awareness and multidisciplinary collaboration. Copyright (c) 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.All authors: Barac A, Carver JR, Ganatra S, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C, Liu JE, Mousavi N, Park JH, Perales MA, Ryan TD, Scherrer-Crosbie M, Steingart RM, Yang EH, Zaha VOriginally published: Journal of the American College of Cardiology. 74(25):3153-3163, 2019 Dec 24.Fiscal year: FY2020Digital Object Identifier:

https://dx.doi.org/10.1016/j.jacc.2019.10.049

Date added to catalog: 2020-01-03

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	31856973	Available		31856973

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of patients with relapsed and refractory hematologic malignancies and is increasingly investigated as a therapeutic option of other malignancies. The main adverse effect of CAR T-cell therapy is potentially life-threatening cytokine release syndrome (CRS). Clinical cardiovascular (CV) manifestations of CRS include tachycardia, hypotension, troponin elevation, reduced left ventricular ejection fraction, pulmonary edema, and cardiogenic shock. Although insults related to CRS toxicity might be transient and reversible in most instances in patients with adequate CV reserve, they can be particularly challenging in higher-risk, often elderly patients with pre-existing CV disease. As the use of CAR T-cell therapy expands to include a wider patient population, careful patient selection, pre-treatment cardiac evaluation, and CV risk stratification should be considered within the CAR T-cell treatment protocol. Early diagnosis and management of CV complications in patients with CRS require awareness and multidisciplinary collaboration. Copyright (c) 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

English